These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
458 related articles for article (PubMed ID: 16249146)
1. Clinical experience with the use of cyclosporin A in psoriasis. Results of a retrospective study. Ojeda R; Sánchez Regaña M; Massana J; Oliete R; Umbert P J Dermatolog Treat; 2005; 16(4):238-41. PubMed ID: 16249146 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of the therapeutic range of whole blood cyclosporin concentration in the treatment of psoriasis. Ieiri I; Nakayama J; Murakami H; Hori Y; Higuchi S Int J Clin Pharmacol Ther; 1996 Mar; 34(3):106-11. PubMed ID: 8705088 [TBL] [Abstract][Full Text] [Related]
3. The efficacy, tolerability and safety of a new oral formulation of Sandimmun--Sandimmun Neoral in severe refractory atopic dermatitis. Atakan N; Erdem C J Eur Acad Dermatol Venereol; 1998 Nov; 11(3):240-6. PubMed ID: 9883436 [TBL] [Abstract][Full Text] [Related]
4. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. Heydendael VM; Spuls PI; Opmeer BC; de Borgie CA; Reitsma JB; Goldschmidt WF; Bossuyt PM; Bos JD; de Rie MA N Engl J Med; 2003 Aug; 349(7):658-65. PubMed ID: 12917302 [TBL] [Abstract][Full Text] [Related]
5. A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis. Yoon HS; Youn JI J Dermatolog Treat; 2007; 18(5):286-90. PubMed ID: 17852632 [TBL] [Abstract][Full Text] [Related]
6. Methotrexate and ciclosporin combination for the treatment of severe psoriasis. Aydin F; Canturk T; Senturk N; Turanli AY Clin Exp Dermatol; 2006 Jul; 31(4):520-4. PubMed ID: 16716153 [TBL] [Abstract][Full Text] [Related]
7. Eosinophils, pruritus and psoriasis: effects of treatment with etretinate or cyclosporin-A. Schopf RE; Hultsch T; Lotz J; Bräutigam M J Eur Acad Dermatol Venereol; 1998 Nov; 11(3):234-9. PubMed ID: 9883435 [TBL] [Abstract][Full Text] [Related]
8. Intermittent cyclosporin A treatment of severe plaque psoriasis. Long-term follow-up of 26 patients. Peluso AM; Bardazzi F; Tosti A; Varotti C Acta Derm Venereol Suppl (Stockh); 1994; 186():90-1. PubMed ID: 8073851 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of preprandial versus postprandial administration of low-dose cyclosporin microemulsion (Neoral) in patients with psoriasis vulgaris. Hashizume H; Ito T; Yagi H; Takigawa M; Kageyama H; Furukawa F; Hata M; Shirahama S; Tanaka M; Higashishiba T; Machida H; Tsushima T; Matsushita K J Dermatol; 2007 Jul; 34(7):430-4. PubMed ID: 17584318 [TBL] [Abstract][Full Text] [Related]
10. Treatment of psoriasis with intermittent short course cyclosporin (Neoral). A multicentre study. Berth-Jones J; Henderson CA; Munro CS; Rogers S; Chalmers RJ; Boffa MJ; Norris PG; Friedmann PS; Graham-Brown RA; Dowd PM; Marks R; Sumner MJ Br J Dermatol; 1997 Apr; 136(4):527-30. PubMed ID: 9155952 [TBL] [Abstract][Full Text] [Related]
11. Clinical and immunohistochemical assessment of the effect of cyclosporin in keratinocytes and dermal dendrocytes in psoriasis. Lago E; Carneiro S; Cuzzi T; Magalhães G; Cássia F; Pessanha F; Ramos-e-Silva M J Cutan Pathol; 2007 Jan; 34(1):15-21. PubMed ID: 17214849 [TBL] [Abstract][Full Text] [Related]
12. Cyclosporin A treatment in severe childhood psoriasis. Pereira TM; Vieira AP; Fernandes JC; Sousa-Basto A J Eur Acad Dermatol Venereol; 2006 Jul; 20(6):651-6. PubMed ID: 16836490 [TBL] [Abstract][Full Text] [Related]
13. Clinical usefulness and patient satisfaction for treatment with low-dose cyclosporin administration in patients with moderate psoriasis vulgaris. Abe M; Ishibuchi H; Syuto T; Sogabe Y; Yokoyama Y; Ishikawa O J Dermatol; 2007 May; 34(5):290-3. PubMed ID: 17408436 [TBL] [Abstract][Full Text] [Related]
14. Initial experience with routine administration of etanercept in psoriasis. de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432 [TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of a fixed-dose cyclosporin microemulsion (100 mg) for the treatment of psoriasis. Shintani Y; Kaneko N; Furuhashi T; Saito C; Morita A J Dermatol; 2011 Oct; 38(10):966-72. PubMed ID: 21545506 [TBL] [Abstract][Full Text] [Related]
16. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502 [TBL] [Abstract][Full Text] [Related]